皮膚がん治療ワクチンの世界市場及びパイプラインインサイト

◆英語タイトル:Global Skin Cancer Vaccine Market & Pipeline Insight 2015
◆商品コード:KUCK502262
◆発行会社(リサーチ会社):KuicK Research
◆発行日:2015年2月
◆ページ数:179
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Multi User(全社内共有可)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Skin cancer incidences are increasing at alarming rates across the world causing high morbidity and mortality. Research and development in field is expected to change the present scenario by providing better therapeutic options for patients. Skin cancer therapeutics available in market used for first-line treatment have modest efficacy which lays emphasis on the development of better products like skin cancer vaccines. Cancer vaccines for different disease indications have proved their worth in medical fraternity by providing better safety and efficacy profiles. Skin cancer vaccines based products are not available in market but they are soon expected to be entering in market in coming years. Market introduction of such products is much awaited to fulfill the unmet medical demand.

Skin cancer vaccine category seems to be one of the most advanced drug category in terms of number of products and types of products. Efforts in this field have allowed the investigators to come with new ideas like implants and oncolytic viruses for the treatment of skin cancer. Such dichotomy is not observable in other cancer categories due to which this segment is expected to occupy significant market share. Also, among different cancer products this skin cancer is expected to generate more revenues in coming years. Initially, it is expected that skin cancer vaccines would be used in combinatorial therapy with conventionally available drugs before becoming main stream treatment. Owing to better pharmacological profiles they are expected to become regular component of therapeutic regime.

Novelty of skin cancer vaccine design is expected to be the major factor in increasing their market penetration. Oncolytic skin cancer vaccines are much awaited products as they have no competitors in present market. Theoretically, they can cure skin cancer at advanced stages and increase the life span of patients but they still needs to be investigated rigorously in clinical trials before market introduction. Skeptics and many medical professional show concern about use of oncolytic viruses as they have pathogenic background and mutate to wild type causing infection in patients. However, such phenomenon has not been observed due to advanced genetic engineering and strict quality control during skin cancer vaccine production. Some of these products are at advanced phases of clinical trials meeting predefine end points for qualifying as a viable pharmacological option.

Implant section of skin cancer vaccine is also expected to make significant impact by decreasing present mortality and morbidity rates. Concept and therapeutic products using implants for treatment has been in pharmaceutical market for several decades. They tend to be more comfortable, require less visits to physicians and higher cost arbitrage coupled with improved technological advancements. This gives a notion that skin cancer vaccines implants will get higher acceptance rates as compared to oncolytic virus based products. However, it should not be compared in case of pharmacological effects because this depends on patients’ medical condition and oncologists’ discretion to utilize best product according to necessity.

“Global Skin Cancer Vaccine Market & Pipeline Insight 2015” Report Highlight

• Introduction to Skin Cancer Vaccine
• Global Skin Cancer Vaccine Market Analysis
• Global Skin Cancer Vaccine Pipeline by Company & Phase
• Global Skin Cancer Vaccine Pipeline: 47 Vaccines
• Majority Skin Cancer Vaccines in Phase-I: 12 Vaccines
• Marketed Skin Cancer Vaccines: 2 (MVax by AVAX Technologies & Melacine by GlaxoSmithKline)
• Personalized Cancer Vaccines: Progress & Possibilities
• Skin Cancer Vaccine Mechanism

【レポートの目次】

1. Introduction to Cancer Vaccines

2. Cancer Vaccines: Mechanism & Innovations
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Introduction to Skin Cancer Vaccine

4. Skin Cancer Vaccine Mechanism

5. Global Skin Cancer Vaccine Market Overview
5.1 Current Market Scenario
5.2 Global Skin Cancer Vaccines Pipeline Overview

6. Global Skin Cancer Vaccine Market Dynamics
6.1 Favorable Market Parameters
6.2 Commercialization Challenges

7. Personalized Cancer Vaccines: Progress & Possibilities

8. Global Skin Cancer Vaccines Market Future Prospects

9. Global Skin Cancer Vaccine Pipeline by Company & Phase
9.1 Preclinical
9.2 Clinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III

10. Marketed Skin Cancer Vaccines Clinical Analysis
10.1 Melanoma Vaccine (MVax®, AVAX Technologies)
10.2 Melanoma Vaccine (Melacine®, GlaxoSmithKline)

11. Suspended & Discontinued Skin Cancer Vaccines Pipeline by Company & Phase
11.1 No Development Reported
11.2 Discontinued

12. Competitive Landscape
12.1 Amgen
12.2 AVAX Technologies
12.3 Corixa
12.4 GlaxoSmithKline
12.5 Gradalis
12.6 Immunocore
12.7 Immune Design
12.8 Merck
12.9 MolMed
12.10 NeoStem Oncology

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Functions of Skin
Figure 3-2: Layers of Skin
Figure 3-3: Types of Skin Cancer
Figure 3-4: Factors Causing Skin Cancer
Figure 4-1: Types of Skin Cancer Treatment
Figure 4-2: Implantable Skin Cancer Vaccine
Figure 4-3: Mechanism of Oncolytic Skin Cancer Vaccine
Figure 4-4: Mechanism of T-VEC Skin Cancer Vaccine
Figure 5-1: Global Skin Cancer Vaccines Pipeline (%), 2015
Figure 5-2: Global Skin Cancer Vaccines Pipeline (Number), 2015
Figure 5-3: No Development Reported in Skin Cancer Vaccines Pipeline (%), 2015
Figure 5-4: No Development Reported in Skin Cancer Vaccines Pipeline (Number), 2015
Figure 5-5: Discontinued Skin Cancer Vaccines in Pipeline (%), 2015
Figure 5-6: Discontinued Skin Cancer Vaccines in Pipeline (Number), 2015
Figure 6-1: Drivers for Skin Cancer Vaccine
Figure 6-2: Skin Cancer Vaccine Market Challenges
Figure 7-1: Overview of Personalized Cancer Vaccines Development
Figure 7-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 7-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine


【掲載企業】

Amgen, AVAX Technologies, Corixa, GlaxoSmithKline, Gradalis, Immunocore, Immune Design, Merck, MolMed,
NeoStem Oncology


【レポートのキーワード】

皮膚がんワクチン、治験、治療薬、パイプライン

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 皮膚がん治療ワクチンの世界市場及びパイプラインインサイト(Global Skin Cancer Vaccine Market & Pipeline Insight 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆